share_log

argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

SEC announcement ·  Jan 18 13:00
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.